Journal of the Korean Association of Oral and Maxillofacial Surgeons

  • 제35권5호
  • /
  • Pages.287-293
  • /
  • 2009
  • /
  • 2234-7550(pISSN)
  • /
  • 2234-5930(eISSN)
대한구강악안면외과학회 (The Korean Association of Oral and Maxillofacial Surgeons)
권호 표지

두경부암 세포주에서 상피성장인자수용체 타이로신 카이네이즈 억제제인 gefitinib의 성장억제에 관한 연구

Growth inhibition in head and neck cancer cell lines by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor

  • Song, Seung-Il (Department of Dentistry, School of Medicine, Ajou University) ;
  • Kim, Myung-Jin (Department of Oral and Maxillofacial Surgery, School of Dentistry, Seoul National University)
  • 발행 : 2009.10.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Cell survival is the result of a balance between programmed cell death and cellular proliferation. Cell membrane receptors and their associated signal transducing proteins control these processes. Of the numerous receptors and signaling proteins, epidermal growth factor receptor (EGFR) is one of the most important receptors involved in signaling pathways implicated in the proliferation and survival of cancer cells. EGFR is often highly expressed in human tumors including oral squamous cell carcinomas, and there is increasing evidence that high expression of EGFR is correlated with poor clinical outcome of common human cancers. Therefore, we examined the antiproliferative activity of gefitinib, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), in head and neck cancer cell lines. SCC-9, KB cells were cultured and growth inhibition activity of gefitinib was measured with MTT assay. To study influence of gefitinib in cell cycle, we performed cell cycle analysis with flow cytometry. Western blot was done to elucidate the expression of EGFR in cell lines and phosphorylation of EGFR and downstream kinase protein, Erk and Akt. Significant growth inhibition was observed in SCC-9 cells in contrast with KB cells. Also, flow cytometric analysis showed G1 phase arrest only in SCC-9 cells. In Western blot analysis for investigation of EGFR expression and downstream molecule phosphorylation, gefitinib suppressed phosphorylation of EGFR and downstream protein kinase Erk, Akt in SCC-9. However, in EGFR positive KB cells, weak expression of active form of Erk and Akt and no inhibitory activity of phosphorylation in Erk and Akt was observed. The antiproliferative activity of gefitinib was not correlated with EGFR expression and some possibility of phosphorylation of Erk and Akt as a predictive factor of gefitinib response was emerged. Further investigations on more reliable predictive factor indicating gefitinib response are awaited to be useful gefitinib treatment in head and neck cancer patients.

키워드

참고문헌

  1. Forastiere AA, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2002;345:1890-1900
  2. Kim ES, Hong WK, Khuri FR. Chemoprevention of aerodigestive tract cancer. Annu Rev Med 2003;53:233-43 https://doi.org/10.1146/annurev.med.53.082901.104015
  3. Shin DM, Hittelman WN, Hong WK. Biomarkers in upper aerodigestive tract tumorigenesis: a review. Cancer Epidemiol Biomark Prev 1994;3:679-709
  4. Jefferies S, Foulkes WD. Genetic mechanisms in squamous cell carcinoma of the head and neck. Oral Oncol 2001;37:115-26 https://doi.org/10.1016/S1368-8375(00)00065-8
  5. Boyle WJ. Growth factor and tyrosine kinase receptors during development and cancer. Curr Opin Oncol 1992;4:156-62 https://doi.org/10.1097/00001622-199202000-00021
  6. Hu G, Liu W, Mendelsohn J. Expression of epidermal growth factor receptor and human papillomavirus E6/E7proteins in cervical carcinoma cells. J Natl Cancer Inst 1997;89:1271-76 https://doi.org/10.1093/jnci/89.17.1271
  7. Iihara K, Shiozaki H, Tahara H. Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Implication for autocrine proliferation. Cancer 1993;71:2902-9 https://doi.org/10.1002/1097-0142(19930515)71:10<2902::AID-CNCR2820711004>3.0.CO;2-J
  8. Grandis JR, Melhem MF, Gooding WE. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-32 https://doi.org/10.1093/jnci/90.11.824
  9. Janmaat ML, Giaccone G. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 2003;8:576-86 https://doi.org/10.1634/theoncologist.8-6-576
  10. Grandis JR, Sol JC. Signaling through the epidermal growth factor receptor during the development of malgnancy. Pharmacol Ther 2004;102:37-46 https://doi.org/10.1016/j.pharmthera.2004.01.002
  11. Albanell J, Codony-Servat J, Rojo F. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/ transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001;61:6500-10
  12. Gullick WJ. The type I growth factoe receptors and their ligands considered as complex system. Endocrine Related Cancer 2001;8:75-82 https://doi.org/10.1677/erc.0.0080075
  13. Yarden Y. The EGFR family and its ligands in human cancer: Signaling mechanisms and therapeutic apportunities. Eur J Cancer 2002;37:S3-S8
  14. Lui VWY, Grandis JR. EGFR-mediated cell cycle regulation. Anticancer Res 2002;22:1-12
  15. Cowley GO, Smith JA, Gusterson BA, Hendler F, Ozanne B. The amount of EGF receptor is elevated on squamous cell carcinomas. Cancer Cells 1984;1:5-10
  16. Partridge M, Gullick WJ, Langdon JD, Sheriff M: Expression of epidermal growth factor receptors on oral squamous cell carcinomas. Br J Oral Max Surg 1988;26:381-6 https://doi.org/10.1016/0266-4356(88)90090-3
  17. Shin DM, Donato NJ, Perez-Soler R, Shin HJC, Wu JY, Zhang P et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clinical Cancer Res 2001;7:1204-13
  18. Maurizio M, Almadori G, Ferrandina G, Distefano M, Romanini ME, Cadoni G et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 1996;74:1253-7 https://doi.org/10.1038/bjc.1996.525
  19. Grandis JR, Mellhem MF, Gooding WE, Day R, Holst VA, Wagner MM et al. Levels of TGF$\alpha$, and EGFR protein in head and neck squamous cell carcinoma and patients survival. J Natl Cancer Inst 1998;90:824-32 https://doi.org/10.1093/jnci/90.11.824
  20. Maiorano E, Favia G, Maisonneuve P, Viale G. Prognostic implications of epidermal growth factor receptor immunoreactivity in squamous cell carcinoma of the oral mucosa. J Pathology 2000;185:167-74 https://doi.org/10.1002/(SICI)1096-9896(199806)185:2<167::AID-PATH70>3.0.CO;2-E
  21. Magne N, Pivot X, Bensadoun RJ, Guardiola E, Poissonnet G, Dassonville O et al. The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy. Eur J Cancer 2001;37:2169-77 https://doi.org/10.1016/S0959-8049(01)00280-5
  22. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-6
  23. Hoffmann TK, Ballo H, Braunstein S, Van Lierop A, Wagenmann M, Bier H. Serum level and tissue expression of cerbB- 1 and c-erbB-2 proto-oncogene products in patients with squamous cell carcinoma of the head and neck. Oral Oncol 2001;37:50-6 https://doi.org/10.1016/S1368-8375(00)00056-7
  24. Khademi B, Shirazi FM, Vasei M, Doroudchi M, Gandomi B, Modjtahedi H et al. The expression of p53, c-erbB-1 and c-erbB- 2 molecules and their correlation with prognostic markers in patients with head and neck tumors. Cancer Letters 2002;184:223-30 https://doi.org/10.1016/S0304-3835(02)00242-2
  25. O-charoenrat P, Rhys-Evans PH, Modjtahedi H, Eccles SA. The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma (Review). Oral Oncology 2002;38:627-40 https://doi.org/10.1016/S1368-8375(02)00029-5
  26. Putti TC, To KF, Hsu HC, Chan AT, Lai GM, Tse G et al. Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: A multicentre immunohistochemical study in the Asia-Pacific region. Histopathology 2002;41:144-51 https://doi.org/10.1046/j.1365-2559.2002.01436.x
  27. Haung SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinoma:Inhibition of damage repair, cell cycle kinetics and tumour angiogenesis. Clin Cancer Res 2000;6:2166-74
  28. Liang K, Ang KK, Milas L, Hunter N, Fan Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiation Biol Phys 2003;57:246-54 https://doi.org/10.1016/S0360-3016(03)00511-X
  29. Ang KK, Andratschke NH, Milas L. Epidermal growth factor receptor and response of head and neck carcinoma to therapy. Int J Radiation Oncology Biol Phys 2004;58:959-65 https://doi.org/10.1016/j.ijrobp.2003.07.010
  30. Cohen EE, Rosen F, Stadler WM. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-7 https://doi.org/10.1200/JCO.2003.10.051
  31. Cohen EE, Kane MA, List MA. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11:8418-24 https://doi.org/10.1158/1078-0432.CCR-05-1247
  32. She QB, Solit DB, Ye Q. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005;8:287-97 https://doi.org/10.1016/j.ccr.2005.09.006
  33. Sriuranpong V, Park JI, Amornphimoltham P. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the interleukin 6/gp130 cytokine system. Cancer Res 2003;63:2948-56
  34. Thompson S, Buck E, Petti F. Epidermal to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenograft to epidermal growth factor receptor inhibition. Cancer Res 2005;65:9455-62 https://doi.org/10.1158/0008-5472.CAN-05-1058
  35. Yauch RL, Januario T, Eberhard DA. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005;11:8686-98 https://doi.org/10.1158/1078-0432.CCR-05-1492
  36. Spector NL, Xia W, Burris H III. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005; 23:2502-12 https://doi.org/10.1200/JCO.2005.12.157
  37. Noro R, Gemma A, Kosaihira S, Kokubo Y, Chen M, Seike M et al. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. BMC Cancer 2006;6:277-98 https://doi.org/10.1186/1471-2407-6-277
  38. Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004;96:1133-41 https://doi.org/10.1093/jnci/djh217